-+ 0.00%
-+ 0.00%
-+ 0.00%

Vaxart says oral H5N1 vaccine candidate VXA-H5-02 delivers 100% survival in ferret challenge study

PUBT·10/08/2026 12:41:15
Listen to the news
Vaxart says oral H5N1 vaccine candidate VXA-H5-02 delivers 100% survival in ferret challenge study
  • Vaxart reported publication of a peer-reviewed preclinical study on its oral H5N1 avian flu vaccine candidate VXA-H5-02.
  • Results were presented as published findings, not as upcoming conference data.
  • Vaccinated ferrets survived a lethal H5N1 challenge, while unvaccinated animals died, supporting the candidate’s protective potential.
  • Data also showed reduced infection markers and broader immune activity against multiple H5 strains, suggesting possible cross-strain coverage.
  • The program remains preclinical, with no human testing reported for VXA-H5-02.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080840PRIMZONEFULLFEED9842173) on October 08, 2026, and is solely responsible for the information contained therein.